EW
NYSEEDWARDS LIFESCIENCES CORPORATION
Technology · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$5.2B
2021
$4.5B
2022
$5.0B
2023
$5.4B
2024
$6.1B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$6.1B
Net Income$1.1B
Gross Profit$4.7B
Oper Income$1.3B
EPS (dil)$1.83
Rev/sh$10.54
FCF/sh$2.32
Book/sh$17.95
Gross M78.0%
Oper M20.8%
Profit M17.6%
FCF M22.0%
ROE10.3%
ROA7.8%
ROIC13.1%
R&D/Rev17.8%
Rev Y/Y11.5%
Rev 3Y CAGR10.8%
EPS Y/Y-73.7%
EPS 3Y CAGR-9.1%
FCF 3Y CAGR11.1%
Payout—
Div/sh—
Shs Chg Y/Y-2.3%
Current Ratio3.72
Quick Ratio3.09
Debt/Eq0.06
Int Coverage62.0×
Net Debt$2.3B cash
Total Debt$598.3M
Cash & Eq$2.9B
Total Assets$13.7B
Oper CF$1.6B
Capex$260.2M
Free CF$1.3B
Buybacks$893.4M
Equity$10.3B
Liabilities$3.4B
Shs Outstand0.58B
SectorTechnology
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $5.2B | $4.5B | $5.0B | $5.4B | $6.1B |
| Gross Profit | $4.0B | $3.7B | $4.0B | $4.3B | $4.7B |
| Operating Income | $1.7B | $1.5B | $1.3B | $1.4B | $1.3B |
| Net Income | $1.5B | $1.5B | $1.4B | $4.2B | $1.1B |
| Diluted EPS | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
| Operating Cash Flow | $1.7B | $1.2B | $895.8M | $542.3M | $1.6B |
| Free Cash Flow | $1.4B | $973.6M | $642.8M | $289.9M | $1.3B |
COMMUNITY · $EW0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.